Articles dans des revues avec comité de lecture (396)
  1. 13. Subbiah, V., Braña, I., Longhi, A., Boni, V., Delord, J. P., Awada, A., Boudou-Rouquette, P., Sarantopoulos, J., Shapiro, G. G., Elias, A. A., Ratan, R., Fernández, C., Kahatt, C., Cullell-Young, M., Siguero, M., Zeaiter, A., & Chawla, S. (2022). Antitumor Activity of Lurbinectedin, a Selective Inhibitor of Oncogene Transcription, in Patients with Relapsed Ewing Sarcoma: Results of a Basket Phase II Study. Clinical cancer research, 28(13), 2762-2770. doi:10.1158/1078-0432.CCR-22-0696
  2. 14. Marta, G. N., Martins-Branco, D., Agostinetto, E., Bruzzone, M., Ceppi, M., Danielli, L., Lambertini, M. M. P. M., Kotecki, N., Awada, A., & de Azambuja, E. (2022). Efficacy of tyrosine kinase inhibitors for the treatment of patients with HER2-positive breast cancer with brain metastases: a systematic review and meta-analysis. ESMO Open, 7(3), 100501. doi:10.1016/j.esmoop.2022.100501
  3. 15. Harding, J. J., Awada, A., Roth, G., Decaens, T., Merle, P., Kotecki, N., Dreyer, C., Ansaldi, C., Rachid, M., Mezouar, S., Menut, A., Bestion, E. N., Paradis, V., Halfon, P., Abou-Alfa, G. K., & Raymond, É. E. (2022). First-In-Human Effects of PPT1 Inhibition Using the Oral Treatment with GNS561/Ezurpimtrostat in Patients with Primary and Secondary Liver Cancers. Liver Cancer, 11(3), 268-277. doi:10.1159/000522418
  4. 16. Moreau, A., Nicaise, C., Awada, A., & Soyfoo, M. S. (2022). Soluble ST2 is increased in systemic lupus erythematous and is a potential marker of lupus nephritis. Clinical and Experimental Rheumatology, 40(5), 897-903. doi:10.55563/clinexprheumatol/eg3a2k
  5. 17. Najem, A., Soumoy, L., Sabbah, M., Krayem, M., Awada, A., Journé, F., & Ghanem, G. E. (2022). Understanding Molecular Mechanisms of Phenotype Switching and Crosstalk with TME to Reveal New Vulnerabilities of Melanoma. Cells, 11(7), 1157. doi:10.3390/cells11071157
  6. 18. Awada, A., Berghmans, T., Clement, P. M. J. P., Cuppens, K., De Wilde, B., Machiels, J. P., Pauwels, P., Peeters, M., Rottey, S., & Van Cutsem, E. (2022). Belgian expert consensus for tumor-agnostic treatment of NTRK gene fusion-driven solid tumors with larotrectinib. Critical reviews in oncology/hematology, 169, 103564. doi:10.1016/j.critrevonc.2021.103564
  7. 19. Saini, K., Punie, K., Twelves, C., Bortini, S., de Azambuja, E., Anderson, S., Criscitiello, C., Awada, A., & Loi, S. (2021). Antibody-drug conjugates, immune-checkpoint inhibitors, and their combination in breast cancer therapeutics. Expert opinion on biological therapy, 21(7), 945-962. doi:10.1080/14712598.2021.1936494
  8. 20. Gombos, A., Venet, D., Ameye, L., Vuylsteke, P., Neven, P., Richard, V., Duhoux, F. F., Laes, J.-F., Rothé, F., Sotiriou, C., Paesmans, M., Awada, A., Guiot, T., Flamen, P., Piccart-Gebhart, M., Ignatiadis, M., & Gebhart, G. (2021). FDG positron emission tomography imaging and ctDNA detection as an early dynamic biomarker of everolimus efficacy in advanced luminal breast cancer. NPJ breast cancer, 7(1), 125. doi:10.1038/s41523-021-00331-8
  9. 21. Najem, A., Wouters, J., Krayem, M., Rambow, F., Sabbah, M., Sales, F., Awada, A., Aerts, S., Journé, F., Marine, J.-C., & Ghanem, G. E. (2021). Tyrosine-Dependent Phenotype Switching Occurs Early in Many Primary Melanoma Cultures Limiting Their Translational Value. Frontiers in oncology, 11, 780654. doi:10.3389/fonc.2021.780654
  10. 22. Castelo-Branco, L., Awada, A., Pentheroudakis, G., Perez-Gracia, J. L., Mateo, J., Curigliano, G., Banerjee, S., Giuliani, R., Lordick, F., Cervantes, A., Tabernero, J., & Peters, S. (2021). Beyond the lessons learned from the COVID-19 pandemic: opportunities to optimize clinical trial implementation in oncology. ESMO Open, 6(5), 100237. doi:10.1016/j.esmoop.2021.100237
  11. 23. Kotecki, N., Kindt, N., Krayem, M., & Awada, A. (2021). New horizons in early drugs development in solid cancers. Current opinion in oncology, 33(5), 513-519. doi:10.1097/CCO.0000000000000766
  12. 24. Schettini, F., Giuliano, M., Lambertini, M., Bartsch, R., Pinato, D. J., Onesti, C. E., Harbeck, N., Lüftner, D., Rottey, S., Van Dam, P. P., Zaman, K., Mustacchi, G., Gligorov, J., Awada, A., Campone, M., Wildiers, H., Gennari, A., Tjan-Heijnen, V. C. G., Cortes, J., Locci, M., Paris, I., Mastro, L. D., De Placido, S., Martin, M., Jerusalem, G., Venturini, S., Curigliano, G., & Generali, D. (2021). Anthracyclines strike back: Rediscovering non‐pegylated liposomal doxorubicin in current therapeutic scenarios of breast cancer. Cancers (Basel), 13(17), 4421. doi:10.3390/cancers13174421
    13. << Précédent 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36
    37     38 39 Suivant >>